MYC and B-cell non-Hodgkin lymphoma: Natural killer T (NKT) cells can be activated by the synthetic glycolipid α-GalCer and this has been shown to lead to anti-tumor responses in different mouse models such as the transgenic Eμ-myc B cell lymphoma and AML-ETO9a leukemia mouse model [28].